ALLMedicine™ Psoriasis Center

Jan 25th, 2022 - Itch is one of the major clinical manifestations of psoriasis, which is closely related with neurogenic inflammation and difficult to control. Colquhounia Root (CR) is a Chinese herb exhibiting broad bioactivities on anti-inflammation. This study ...

Jan 24th, 2022 - Psoriasis is a chronic inflammatory illness that affects 2 to 3% of the world's population. Granulysin (GNLY), along with granzyme and perforin, is a cytolytic antimicrobial peptide (AMP) released from the granules of both natural killer (NK) cell...

Jan 23rd, 2022 - We report a female patient presenting with generalized pustular psoriasis and hypogammaglobulinemia due to digenic mutations in IL-36RA and SEC61A1. The patient presented with recurrent fevers, elevated inflammatory markers, hepatosplenomegaly, an...

Jan 23rd, 2022 - Type I IFN (IFN-I) is a family of cytokines involved in the pathogenesis of autoimmune and autoinflammatory diseases such as psoriasis. SIDT1 is an ER-resident protein expressed in the lymphoid lineage, and involved in anti-viral IFN-I responses i...

Jan 22nd, 2022 - Generalized pustular psoriasis (GPP) is a rare disease that has only recently benefited from a consistent definition and clinical coding standard. A lack of disease awareness combined with clinical similarities to other types of psoriasis have his...

Feb 7th, 2021 - This evidence- and consensus-based guideline on the treatment of psoriasis vulgaris was developed following the EuroGuiDerm Guideline and Consensus Statement Development Manual. The second part of the guideline provides guidance for specific clini...

Jan 7th, 2021 - Topical treatment is crucial for the successful management of plaque psoriasis. Topicals are used either as a stand-alone therapy for mild psoriasis or else in combination with UV or systemic treatment for moderate-to-severe disease. For the choic...

Dec 11th, 2020 - Psoriasis is a highly prevalent chronic, inflammatory multisystem disease with a considerable impact on patients' quality of life and the healthcare system. This report presents the recommendations developed by the Portuguese Psoriasis Group of th...

Nov 5th, 2020 - Owing to the evolving COVID-19 pandemic and emerging data regarding immunosuppressant therapies for inflammatory cutaneous diseases, dermatologists are being encouraged to reevaluate their patients' treatment regimens to minimize any potential ris...

Sep 7th, 2020 - To provide guidance about management of psoriatic disease during the coronavirus disease 2019 (COVID-19) pandemic. A task force (TF) of 18 physician voting members with expertise in dermatology, rheumatology, epidemiology, infectious diseases, and...

Jan 21st, 2022 - The investigators are planning to find the right modification of traditionally used risk scores (PASI, DLQI) in patients with psoriasis of different severity to guide the treatment that could potentially extend life, improve cardiovascular outcome...

Jan 19th, 2022 - Basal cell carcinoma occurs most often on areas of the skin that are exposed to the sun, such as head and neck. The most commonly found clinical feature of Basal Cell Carcinoma (BCC) is an elevated tumor with a pearly and translucent margin and te...

Jan 19th, 2022 - This will be a multicenter, double-blind, double-dummy, placebo controlled, randomized study to evaluate the efficacy and safety of AUR101 in patients with moderate-to-severe psoriasis. Approximately 128 patients with chronic moderate-to-severe pl...

Jan 14th, 2022 - The primary objectives of this study are to determine the effect of apremilast on aortic vascular inflammation, cardiometabolic biomarkers and body composition in patients with moderate-severe psoriasis. FDG-PET/CT will be used to assess vascular ...

Jan 13th, 2022 - Core study: After providing informed consent patients will be screened for eligibility for a period of 1-4 weeks prior to inclusion into the study. If eligible, patients will then be randomized to one of the two treatment arms, which are the follo...

Jan 21st, 2022 - The US Food and Drug Administration (FDA) today approved risankizumab-rzaa (Skyrizi) for a second indication — treating adults with active psoriatic arthritis (PsA) — making it the second anti-interleukin 23 monoclonal antibody available to treat ...

Jan 19th, 2022 - Advances in the treatment of solid tumors and hematologic malignancies have resulted in the development of thera-peutic regimens that can be administered at various points in a patient’s care. However, as patients’ disease progresses, adverse effe...

Jan 18th, 2022 - Steven Feldman, MD, PhD, looks back on the trajectory of treatments for both mild and severe psoriasis, from the advent of topical corticosteroid sprays to the revolution of current biologics. In tracing the changing therapeutic landscape, Dr Feld...

Jan 18th, 2022 - NEW YORK (Reuters Health) - Risankizumab, an inhibitor of interleukin 23, provides some relief for patients with active psoriatic arthritis (PsA) whose symptoms have responded poorly to standard treatments, according to 24-week results of a phase-...

Jan 6th, 2022 - Vitiligo is a chronic dermatologic condition that negatively affects quality of life (QOL), with substantial burden on the psychosocial well-being of patients. 1 There is no cure, and current treatment modalities are aimed at controlling the chroni.